TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its ...
Healthcare stayed in the red while the broader market rose, yet Immutep soared on a major deal, PolyNovo won an ... Read More ...
Professor Andrew 'Andy' Whitelaw, Chair in Neonatology at the University of Bristol and consultant neonatologist at Southmead ...
Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease characterised by a ‘vicious vortex’ of ...
The world's largest crocodile in captivity until its death last year is going on display in Far North Queensland, as more ...
Biogen Canada Inc. is encouraged by the recent Health Technology Assessment (HTA) evaluations issued by Canada’s Drug Agency ...
Two mutated alleles of the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in the autosomal recessive ...
Dyne Therapeutics, citing trial data, said it will ask the FDA to approve DYNE-251, its therapy for DMD amenable to exon 51 skipping.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback